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The prevalence of blood group antigens and phenotypes varies 
significantly in Brazil. To ensure a proper rare blood supply, it is 
essential to establish a local and regional database of rare donors 
connected to the national registry. The objective of this study was 
to create a database of rare blood donors in the northern region 
of southern Brazil. From November 2011 to December 2018, red 
blood cell (RBC) phenotyping and genotyping were performed 
on common and high-prevalence antigens in donors and patients 
in southern Brazil. During this study period, 17 patients and 33 
blood donors with rare phenotypes were identified. Six patients 
had already been alloimmunized to clinically significant antigens. 
Patients with the following phenotypes (i.e., negative for high-
prevalence antigens) were found: Yt(a–), Jk(a–b–), Lu(a–b–), Oh 
(Bombay), Tc(a–), k–, and Fy(a–b–). Among the donors, Kp(a+b–), 
Fy(a–b–), Lu(a–b–), and k– phenotypes were identified. We 
also found four donors with the weak D type 18 phenotype. 
In conclusion, we observed that the prevalence of rare blood 
phenotypes in our region corresponds more to the prevalence 
found in the Caucasian population when compared with other 
regions in Brazil. Our results show the importance of continuous 
screening for rare donors in different regions of the country and 
the creation of a local database to support RBC transfusions in 
patients who need rare blood. Immunohematology 2020;36: 
152–156.
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Currently, 343 red blood cell (RBC) antigens are grouped 
in 43 blood group systems according to the International 
Society of Blood Transfusion.1 These antigens induce the 
formation of RBC alloantibodies that are involved in blood 
incompatibilities, leading to immediate and delayed hemolytic 
transfusion reactions, and hemolytic disease of the fetus and 
newborn.2
The definition of rare blood or a rare donor is not yet well 
established. In most countries, a blood donor or a patient is 
considered rare when their phenotype in the population 
is found in 1:1000 or fewer individuals. Additionally, a 
combination of negative common antigens is also considered 
rare for the provision of blood to patients with multiple 
specificities of alloantibodies, frequently involving antigens 
of the Rh blood group system.3
The most common blood group systems with antibodies 
of clinical significance are ABO, Rh, Kell, Duffy, Kidd, and 
MNS; antibodies with clinical significance against Lutheran, 
Gerbich, Colton, and Cartwright antigens are considered 
rare.4 With increased life expectancy, the frequency of RBC 
alloantibodies in patients receiving regular transfusions has 
expanded, raising the difficulty to find compatible blood, and 
increasing the risk of delayed hemolytic transfusion reactions.5
The blood supply may become a challenge when a patient 
produces an alloantibody to an antigen of high prevalence 
or produces antibodies against multiple common antigens. 
Securing a blood supply for such situations requires access to 
a blood inventory widely phenotyped, as well as a rare donor 
registry. A way of accomplishing this initiative is by screening 
routinely for rare phenotypes in blood donors.6
In Brazil, there are few studies about the prevalence of rare 
blood types in the population, and the existing results reveal 
that within the same state, differences occur depending on the 
region.7 Until 2014, there was no national rare donor program, 
and the inventories of frozen RBCs were kept in two centers: 
Albert Einstein Hospital and Sírio Libanês Hospital. In 2014, 
the Ministry of Health, through the General Coordination of 
Blood, established a technical committee to implement and 
support a national rare donor program and selected four blood 
centers in strategic regions of the country to screen for rare 
donors. Although this national program emerged to conduct 
rare donor screening and to create a national registry of rare 
donors to meet the needs of patients with rare phenotypes, this 
supply is still a challenge in the country.8
The aim of this study was to create a database of rare 
donors from the northern region of southern Brazil to meet 
the needs of our patients and be part of the national registry to 
help increase the supply of rare blood across the country.
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Material and Methods
Study Design and Sample Selection
This linear, cross-sectional study comprises a database of 
donors and patients in the northern region of the state of Rio 
Grande do Sul, Brazil, from November 2011 to December 2018. 
We analyzed patients and blood donors with rare phenotypic 
composition, alloimmunized or not, and who were negative for 
high-prevalence antigens.
Laboratory Testing
RBC phenotyping was performed in tube, in gel (Bio-Rad; 
Lagoa Santa, MG, Brazil), and in glass microsphere column 
agglutination technology (Ortho Clinical Diagnostics, Raritan, 
NJ) using commercial antisera according to the manufactur-
er’s instructions.
RBC genotyping was carried out by polymerase chain 
reaction using laboratory-developed tests, a commercial 
kit (HEA BeadChip; Immucor, Warren, NJ), and Sanger 
sequencing when necessary.
Statistical Analysis
The research instrument for data collection data was 
filled with computerized system information in a program 
(Excel; Microsoft, Redmond, WA), with which we performed 
a descriptive statistical analysis. For patients, the variables 
analyzed were patient’s diagnosis, age, gender, transfusion 
history, transfusion modality, pre-transfusion testing, and 
RBC genotyping. For donors, the variables were age, gender, 
number of donations in 1 year, and RBC genotyping.
Results
During the study period, 17 patients and 33 blood donors 
with rare phenotypes were identified by extended phenotyping 
and/or genotyping. Among the patients, 6 were male and 11 
were female. The average age was 43 years, and the average 
transfusion was 5 units of packed RBCs. The profile of the 
patients with rare blood types is displayed in Table 1. Among 
donors, 19 were male and 14 were female, with an average age 
of 38 years and an average donation of three times a year.
Fy(a–b–) with the FY*B-67C/FY*B-67C genotype was 
the most prevalent phenotype found in patients and donors, 
followed by the k– phenotype (Table 2).
Table 3 highlights that, although the most frequent 
phenotype combinations with lack of common antigens found 
in patients and donors are R1R1, R2R2, rr and K–, Fy(a–), 
Jk(a–), S–, more donors than patients were found with these 
combinations.
Table 1. Profile of patients with rare blood types
Age, years Gender Diagnosis Rare blood type Antibodies Transfusion modality Transfusion history (n*)
79 F Total hip prosthesis Yt(a–) Anti-c, -Jka, -Yta Scheduled 1 
34 F Sickle cell disease Fy(a–b–) — Scheduled 2 
81 F Femur fracture Fy(a–b–) Anti-N Reserved 4 
55 M Cardiac insufficiency Fy(a–b–) Anti-E, -Fya Routine 2 
3 F Sacrolite Lu(a–b–) Anti-M Reserved NP
74 M Myelodysplastic syndrome k– — Routine 28 
85 M Myelodysplastic syndrome k– — Scheduled 17 
35 F Pregnancy Fy(a–b–) Anti-D Laboratory tests NP
9 F Congenital hip displacement Oh Anti-H Laboratory tests 2 
27 F Sickle cell trait Tc(a–) — Laboratory tests NP
24 M Sickle cell disease Tc(a–) Anti-Tca Routine 7 
69 M Arthritis k– Anti-k Urgency 2
31 F Pregnancy k– — Laboratory tests NP
86 F Subtrochanteric fracture Fy(a–b–) — Urgency 4
19 F Test requested Jk(a–b–) — Laboratory tests NP
M Newborn with low weight k– — Urgency 4
75 F Connective tissue neoplasm k– — Reserved 4
*Number of red blood cell units transfused. NP = not provided.
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Regarding the packed RBC units transfused in the 17 
patients with rare phenotypes, 6 of them had never received a 
previous transfusion. Among the 11 transfused patients, there 
was a variation between 1 and 28 RBC units transfused, and 
6 of these patients had one or more clinically significant RBC 
antibodies.
Discussion
In the present study, 17 patients with rare phenotypes 
were identified, 2 of them with sickle cell disease (SCD) 
receiving a transfusion average of 5 RBC units per year 
and 6 patients with clinically significant alloantibodies. 
An observational work, performed in the Blood Center of 
Alagoas in Brazil, with 102 patients with SCD, has shown 
that patients receiving up to 5 RBC units per year were 16 
times more likely to develop alloantibodies than those with 
other diagnoses receiving sporadic transfusions.9 Another 
study carried out in Chile, with 4716 general patients and 
an average of 4.2 RBC units transfused, showed a 1.02 
percent prevalence for alloimmunization.10 In patients 
with SCD, the rate of alloimmunization varies from 7 to 47 
percent depending on age and exposure to RBC transfusions 
compared with 5 percent among other patients with chronic 
anemia.11–13 In these situations, if these patients are previously 
alloimmunized against high-prevalence antigens or against 
multiple common antigens, the blood supply becomes a 
challenge, and a database of rare donors becomes essential to 
avoid hemolytic transfusion reactions.6 In our patient cohort, 
the negative phenotypes for high-prevalence antigens found 
were Yt(a–), Jk(a–b–), Lu(a–b–), Oh (Bombay), Tc(a–), k–, and 
Fy(a–b–).
Although no donor with the Yt(a–) phenotype was found, 
anti-Yta is rarely clinically significant, despite reports of in 
vivo hemolysis, which challenges transfusion support in these 
patients. Thus, the clinical significance of the rare antibodies 
must be assessed individually, and RBC survival tests in vitro, 
such as monolayer monocyte assay, may be necessary.14,15
The Jk(a–b–) phenotype found in one of our patients is 
rare in most populations but is more common in Polynesians. 
The anti-Jk3 developed by these individuals is clinically 
significant and can be difficult to identify, because their 
antibody levels may drop over time.16 In our study, no donor 
with this phenotype has yet been identified, and the Jk(a–b–) 
patient has not yet needed a transfusion. Nonetheless, this 
finding has stimulated an ongoing search for this phenotype 
in our donors and in national and international rare donor 
registries.
In our study, the Lu(a–b–) phenotype was found in 
one patient and one donor. Although the patient has not yet 
been alloimmunized, the risk of alloimmunization should 
be considered, since transfusion incompatibility can cause 
delayed and mild hemolytic transfusion reactions.
Table 2. Patients and donors with rare phenotypes
Patients n Donors n
Yt(a–) 1 Weak D type 18 4
Jk(a–b–) 1 CCdee 5
Fy(a–b–) 6 Fy(a–b–) 11
Lu(a–b–) 1 Lu(a–b–) 1
Tc(a–) 2 Kp(a+b–) 1
Oh 1
k– 5 k– 11
Total 17 33
Table 3. Patients and donors with phenotypic combination of 
negative common antigens 
Phenotypic combination Patients, n Donors, n
R1R1 K– Fy(a–) Jk(a–) S– 2 11
R1R1 K– Fy(a–) Jk(a–) s– 0 6
R1R1 K– Fy(a–) Jk(b–) S– 6 4
R1R1 K– Fy(a–) Jk(a–) s– 2 2
R1R1 K– Fy(b–) Jk(a–) S– 1 14
R1R1 K– Fy(b–) Jk(a–) s– 0 6
R1R1 K– Fy(b–) Jk(b–) S– 1 13
R1R1 K– Fy(b–) Jk(b–) s– 1 4
R2R2 K– Fy(a–) Jk(a–) S– 0 4
R2R2 K– Fy(a–) Jk(b–) S– 0 4
R2R2 K– Fy(b–) Jk(a–) S– 1 5
R2R2 K– Fy(b–) Jk(b–) S– 1 2
R0R0 K– Fy(a–) Jk(a–) S– 2 2
R0R0 K– Fy(a–) Jk(b–) S– 1 1
R0R0 K– Fy(b–) Jk(a–) S– 0 1
rr K– Fy(a–) Jk(a–) S– 1 7
rr K– Fy(a–) Jk(a–) s– 1 1
rr K– Fy(a–) Jk(b–) S– 0 5
rr K– Fy(a–) Jk(b–) s– 4 1
rr K– Fy(b–) Jk(a–) S– 0 1
rr K– Fy(b–) Jk(a–) s– 0 2
rr K– Fy(b–) Jk(b–) S– 1 2
rr K– Fy(b–) Jk(b–) s– 0 3
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The Oh (Bombay) phenotype, in one of our white patients, 
is almost exclusively found in individuals from India, with 
an incidence of 1 in 10,000. In those of European descent, 
the incidence is approximately 1 in 1,000,000, but in Brazil, 
11 families of European descent with the Bombay phenotype 
have been identified as a result of consanguineous marriages; 
these families are found in specific geographical areas, 
including the northeast and southern regions of Brazil.17 
Patients with this rare phenotype naturally produce anti-H 
of clinical significance, leading to immediate hemolytic trans-
fusion reactions.18
Antibodies to Cromer antigens are rarely found, although 
anti-Tca can cause severe hemolytic transfusion reactions.19 In 
our cohort, we found two patients with the Tc(a–) phenotype: 
twin brothers, one with SCD and anti-Tca and the other with 
SCD traits and no antibodies. To date, no donor with this 
phenotype has been found in our region and in the national 
registry; therefore, this patient is being monitored to avoid 
incompatible transfusion.
The k– phenotype was not so rare (around 1%) in the 
studied population, both in patients and in donors; therefore, 
it should not be considered an important transfusion challenge 
as the other rarer phenotypes.
Although our donors and patients belong to a region of 
Brazil with inhabitants predominantly of European ethnicity, 
all Fy(a–b–) individuals found had the GATA mutation, which 
reinforces the miscegenation existing in Brazil. Therefore, 
there would not be a problem with transfusion compatibility 
for patients with this phenotype.
Our study identified 33 donors with rare RBC phenotypes, 
19 were male (57.6%), the average age was 38 years, no 
donor was under 23 years old, and the oldest was 68 years 
old, with an average of three donations per year. Phenotypic 
combinations found in these donors with lack of common 
antigens considered rare such as c– E– K– Fy(a–) Jk(a–) s–; 
C– e– K– Fy(a–) Jk(a–) S–; and D– C– E– K– Fy(a–) Jk(b–) 
S– were not present in any patient.
Among the donors, the Kp(a+b–) phenotype, which is very 
rare in other regions of Brazil, was identified, showing that in 
the south, even with racial admixture, we can find more rare 
phenotypes associated with individuals of European descent. 
Interestingly, we had four donors with the weak D type 18 
phenotype. This phenotype had been previously reported in 
a single study that described a case of a donor identified by 
molecular biology, after being typed 17 times in previous 
donations as D–.20 The presence of this phenotype in our 
donors shows a founding and restricted effect in this southern 
region of Brazil.
Our study also shows that for phenotypic combinations 
with lack of common antigens found in patients and donors, 
at least one donor was found for each combination. Thus, 
if there is a need for transfusion, there is the possibility of 
seeking more donors in the donor’s family, already identified, 
and directing the collection of packed RBCs for apheresis.
Conclusion
Our results show that some rare blood types found in 
this southern region of Brazil correspond more to those found 
in European populations than in other states and regions of 
Brazil, where miscegenation between Europeans, Africans, 
and Indians is greater. This study showed the complexity of 
transfusion support in patients with rare phenotypes and the 
importance of continuous investment in RBC phenotyping 
and genotyping in different regions of Brazil. It is important to 
emphasize that there are patients who do not have compatible 
donors, and it is necessary to intensify strategies in specific 
regions of the country, such as the creation of a local database 
to identify and subsidize alternative approaches, when nec-
essary, for patients with rare blood types.
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